Promotes Weight Loss

The main benefit of this FDA-approved drug is to help overweight and obese people achieve healthier weight and lower their risk for weight-related medical conditions. An overwhelming body of clinical evidence supports this:
1. In overweight/obese individuals with type 2 diabetes, administration of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) resulted in significantly greater weight reduction. [2]
2. In non-diabetic patients, three phase 3 trials of naltrexone SR plus bupropion SR (NB) demonstrated significant weight loss without any adverse side effects. [3-5]
3. When combined with lifestyle intervention and modest calorie reduction, the naltrexone–bupropion combination appears to achieve clinically significant weight loss (over 5% of total body weight) after 6 months to 1 year of treatment. [6]
4. A study found that contrave treatment was associated with 3 to 7% weight loss and improvements in obesity-related comorbidities and cardiovascular risk factors. [7]
5. Patients who received 1 year of naltrexone ER/bupropion ER combination therapy with greater than 5% weight lost are likely to maintain clinically significant results. [8]
6. In overweight and obese patients, naltrexone/bupropion (NB) combination therapy was associated with significantly greater weight loss. [9]
7. In patients with uncomplicated obesity, combined bupropion and naltrexone therapy caused gradual sustained weight loss over 48 weeks. [10]
8. In middle-aged white females, contrave treatment significantly reduced weight. [11-13]
9. In obese mice, contrave significantly reduced weight by increasing the activity of POMC cells, which are peptides that play an integral role in weight regulation. [14]
10. Direct injection of bupropion and naltrexone in mice produced greater reduction in food intake. [15-16]
11. In obese patients, contrave treatment reduced body fat and visceral adipose tissue. [17]
12. A study found that contrave has a greater weight loss efficacy than other FDA-approved drugs for obesity, such as orlistat and lorcaserin. [18]
13. A study also found that contrave has favorable effects on obesity or medication-related weight gain. [19]